| Belantamab mafodotin for the treatment of multiple myeloma: an overview of the clinical efficacy and safety M Offidani, L Corvatta, S Morè, A Olivieri Drug design, development and therapy, 2401-2415, 2021 | 35 | 2021 |
| Autologous stem cell transplantation in multiple myeloma: where are we and where do we want to go? S Morè, L Corvatta, VM Manieri, F Saraceni, I Scortechini, G Mancini, ... Cells 11 (4), 606, 2022 | 24 | 2022 |
| Novel experimental drugs for treatment of multiple myeloma M Offidani, L Corvatta, S Morè, A Olivieri Journal of experimental pharmacology, 245-264, 2021 | 22 | 2021 |
| Real‐world assessment of treatment patterns and outcomes in patients with relapsed‐refractory multiple myeloma in an Italian haematological tertiary care centre S Morè, L Corvatta, MV Manieri, A Olivieri, M Offidani British Journal of Haematology 201 (3), 432-442, 2023 | 11 | 2023 |
| Monoclonal antibodies: Leading actors in the relapsed/refractory multiple myeloma treatment S Morè, MT Petrucci, L Corvatta, F Fazio, M Offidani, A Olivieri Pharmaceuticals 13 (12), 426, 2020 | 8 | 2020 |
| Developments in consolidation and maintenance strategies in post-remission multiple myeloma S Morè, L Corvatta, L Maracci, B Costantini, A Olivieri, M Offidani Expert Review of Hematology 13 (4), 351-362, 2020 | 6 | 2020 |
| Long term survival in multiple myeloma patients: A multicenter Italian experience F Fazio, M Gherardini, T Za, E Rossi, F Di Landro, S Morè, MV Manieri, ... Blood 140 (Supplement 1), 7147-7149, 2022 | 2 | 2022 |
| An update on novel multiple myeloma targets M Offidani, L Corvatta, S Morè, MV Manieri, A Olivieri Expert Review of Hematology 15 (6), 519-537, 2022 | 2 | 2022 |
| Maintenance therapy in multiple myeloma: Two is not always better than one M Offidani, S Morè, L Corvatta British Journal of Haematology 201 (2), 181-182, 2023 | 1 | 2023 |
| Reviews in hematologic malignancies F Saraceni, S Morè Frontiers in Oncology 12, 1105523, 2022 | | 2022 |
| Subcutaneous bortezomib-containing regimens as up-front treatment of newly diagnosed transplant-eligible multiple myeloma patients: a retrospective, non-interventional … I Rizzello, M Cavo, L Dozza, E Rivolti, MT Petrucci, V De Stefano, ... Leukemia & Lymphoma 62 (8), 1897-1906, 2021 | | 2021 |
| Dynamic Features Occurring during Multiple Myeloma Course Can Modify the Outcome Predicted at Diagnosis By R-ISS Stage M Offidani, L Corvatta, S Morè, V Mori, S Gentili, KB Garvey, A Bossi, ... Blood 128 (22), 3263, 2016 | | 2016 |
